FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2975559793> ?p ?o ?g. }

• W2975559793 endingPage "3389" @default.
• W2975559793 startingPage "3383" @default.
• W2975559793 abstract "Nasal polyposis (NP) is a frequent problem during adulthood. Treatment of NP is primarily based on drugs, such as oral or topical steroids and in some types, by surgery. Despite of available therapeutic options for NP, recurrence after polypectomy is found. Vascular endothelial growth factor (VEGF) is a known factor involved in NP. Bevacizumab is a monoclonal antibody, which acts against VEGF.Regarding the availability of bevacizumab and its use in ophthalmic off-label application, in this study, we hypothesized that it could be a choice of non-invasive treatment. The researchers aimed at evaluating the use of bevacizumab in vitro on the growth of NP.In this experimental study, the researchers used eight non-allergic NP tissues from patients admitted for polypectomy clinic of Imam Reza Hospital, Mashhad. Tissues were cultured in DMEM medium based on standard protocols in the presence or absence of bevacizumab (10 to 250 μM) then incubated. The mean of the responses was reported. The level of VEGF and MTT test for NP epithelial cell viability were determined for each group. Data were analyzed using the SPSS software.The researchers demonstrated that bevacizumab leads to a decrease in the level of VEGF (the most common cause of angiogenesis in NP) in media culture of NP, dose-dependently (P<0.001). The highest mean was related to the 10-μM group and the least mean was related to the 250-μM group. In MTT test after 5 days, it was shown that the percentage of viable epithelial NP cells (due to apoptosis) was decreased dose-dependently and could lead to resolving NP tissue (P<0.001), significantly.This study showed that bevacizumab could help decrease the growth of NP tissue dose-dependently in organ culture in vitro by inhibiting VEGF. It seems that bevacizumab could be a good candidate for the treatment of non-allergic NP." @default.
• W2975559793 created "2019-10-03" @default.
• W2975559793 creator A5004499938 @default.
• W2975559793 creator A5013371095 @default.
• W2975559793 creator A5023573647 @default.
• W2975559793 creator A5085865360 @default.
• W2975559793 date "2019-09-01" @default.
• W2975559793 modified "2023-10-18" @default.
• W2975559793 title "<p>Effect Of Bevacizumab On Growth Of Human Nasal Polyposis In Vitro; An Off-Label Use Of Anti-Angiogenic Agent For Nasal Polyposis Treatment</p>" @default.
• W2975559793 cites W141004785 @default.
• W2975559793 cites W1481626642 @default.
• W2975559793 cites W1540540538 @default.
• W2975559793 cites W1964262288 @default.
• W2975559793 cites W1980031127 @default.
• W2975559793 cites W1986473552 @default.
• W2975559793 cites W1991092593 @default.
• W2975559793 cites W1994953133 @default.
• W2975559793 cites W2009197030 @default.
• W2975559793 cites W2014231432 @default.
• W2975559793 cites W2022254881 @default.
• W2975559793 cites W2029126623 @default.
• W2975559793 cites W2042261909 @default.
• W2975559793 cites W2044554818 @default.
• W2975559793 cites W2069526080 @default.
• W2975559793 cites W2080324444 @default.
• W2975559793 cites W2081633887 @default.
• W2975559793 cites W2089585165 @default.
• W2975559793 cites W2100027888 @default.
• W2975559793 cites W2102983422 @default.
• W2975559793 cites W2104103989 @default.
• W2975559793 cites W2114159573 @default.
• W2975559793 cites W2118880062 @default.
• W2975559793 cites W2140744577 @default.
• W2975559793 cites W2157654198 @default.
• W2975559793 cites W2159044113 @default.
• W2975559793 cites W2185828908 @default.
• W2975559793 cites W2413945692 @default.
• W2975559793 cites W2414689004 @default.
• W2975559793 cites W2517542704 @default.
• W2975559793 cites W2553604366 @default.
• W2975559793 cites W2790480285 @default.
• W2975559793 cites W3047533959 @default.
• W2975559793 cites W3147834664 @default.
• W2975559793 cites W48212629 @default.
• W2975559793 cites W55291501 @default.
• W2975559793 doi "https://doi.org/10.2147/dddt.s219724" @default.
• W2975559793 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6767760" @default.
• W2975559793 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31576112" @default.
• W2975559793 hasPublicationYear "2019" @default.
• W2975559793 type Work @default.
• W2975559793 sameAs 2975559793 @default.
• W2975559793 citedByCount "2" @default.
• W2975559793 countsByYear W29755597932021 @default.
• W2975559793 countsByYear W29755597932022 @default.
• W2975559793 crossrefType "journal-article" @default.
• W2975559793 hasAuthorship W2975559793A5004499938 @default.
• W2975559793 hasAuthorship W2975559793A5013371095 @default.
• W2975559793 hasAuthorship W2975559793A5023573647 @default.
• W2975559793 hasAuthorship W2975559793A5085865360 @default.
• W2975559793 hasBestOaLocation W29755597931 @default.
• W2975559793 hasConcept C121608353 @default.
• W2975559793 hasConcept C126322002 @default.
• W2975559793 hasConcept C146285616 @default.
• W2975559793 hasConcept C159654299 @default.
• W2975559793 hasConcept C167734588 @default.
• W2975559793 hasConcept C202751555 @default.
• W2975559793 hasConcept C203014093 @default.
• W2975559793 hasConcept C2776694085 @default.
• W2975559793 hasConcept C2777025900 @default.
• W2975559793 hasConcept C2777802072 @default.
• W2975559793 hasConcept C2778435480 @default.
• W2975559793 hasConcept C2780394083 @default.
• W2975559793 hasConcept C2780581329 @default.
• W2975559793 hasConcept C2780783641 @default.
• W2975559793 hasConcept C526805850 @default.
• W2975559793 hasConcept C542903549 @default.
• W2975559793 hasConcept C55493867 @default.
• W2975559793 hasConcept C71924100 @default.
• W2975559793 hasConcept C86803240 @default.
• W2975559793 hasConcept C90924648 @default.
• W2975559793 hasConcept C98274493 @default.
• W2975559793 hasConceptScore W2975559793C121608353 @default.
• W2975559793 hasConceptScore W2975559793C126322002 @default.
• W2975559793 hasConceptScore W2975559793C146285616 @default.
• W2975559793 hasConceptScore W2975559793C159654299 @default.
• W2975559793 hasConceptScore W2975559793C167734588 @default.
• W2975559793 hasConceptScore W2975559793C202751555 @default.
• W2975559793 hasConceptScore W2975559793C203014093 @default.
• W2975559793 hasConceptScore W2975559793C2776694085 @default.
• W2975559793 hasConceptScore W2975559793C2777025900 @default.
• W2975559793 hasConceptScore W2975559793C2777802072 @default.
• W2975559793 hasConceptScore W2975559793C2778435480 @default.
• W2975559793 hasConceptScore W2975559793C2780394083 @default.
• W2975559793 hasConceptScore W2975559793C2780581329 @default.
• W2975559793 hasConceptScore W2975559793C2780783641 @default.
• W2975559793 hasConceptScore W2975559793C526805850 @default.
• W2975559793 hasConceptScore W2975559793C542903549 @default.
• W2975559793 hasConceptScore W2975559793C55493867 @default.

• next